Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $146.38 +0.58%
Revenue Growth %: +30.8%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
PBNK, FNRN, MSGK, More
Revenue Growth %: +30.8%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
PBNK, FNRN, MSGK, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.94, $0.77 better than the analyst estimate of $1.17. Revenue for the quarter came in at $811 million versus the consensus estimate of $766.85 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades First Busey (BUSE) to Market Perform
- Silvercrest Asset Management (SAMG) Tops Q3 EPS by 5c
- Sanofi (SNY) Tops Q3 EPS by 199c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
